Outpatient parenteral antimicrobial therapy (OPAT) is an established treatment option for patients with a variety of infections who require a period of intravenous therapy, are clinically stable, and do not require continuous monitoring. Many patients with fungal infections require prolonged therapy due to resistance or intolerance to oral antifungal agents. Despite the widespread use of OPAT by infection specialists, antifungal agents appear infrequently used in this setting. We suggest that with appropriate patient selection, patients with fungal infections could successfully be treated on OPAT.
| INTRODUC TI ON
Outpatient parenteral antimicrobial therapy (OPAT), the administration of intravenous antimicrobials to patients in the ambulatory setting, has become established as a suitable alternative to inpatient therapy in appropriate patients. 1, 2 Generally, patients selected for OPAT require a period of several days to weeks of parenteral therapy for infections whilst remaining otherwise well and fit for discharge from hospital. 1 Ireland; 47% and 14%, respectively, reported experience of using amphotericin B in OPAT. 4, 5 In many patients, therapy with triazole antifungals, which are available as oral agents, is the preferred treatment option; however, in certain circumstances the triazoles may not be appropriate due to resistance, toxicity or drug-drug interactions. Additionally, the toxicity of antifungal agents may be a concern in an outpatient setting, and close monitoring or cautious adjustment of treatment on a frequent basis is required. This may be an additional barrier to OPAT in this patient cohort, particularly in less well-resourced OPAT programmes. The provision of parenteral antifungal therapy is possible in the OPAT setting provided there is careful and considered patient selection and appropriate safety monitoring, and follow-up with an infection specialist is implemented. Of the three echinocandins, caspofungin undergoes more extensive hepatic metabolism, requiring careful consideration of drug-drug interactions prior to commencing therapy. 18 Known interactions include reduction in serum tacrolimus levels when coadministered with caspofungin, whilst cyclosporin will increase serum levels of caspofungin. The use of enzyme-inducing drugs such as rifampicin, phenytoin, efavirenz and carbamazepine may reduce serum caspofungin levels. Considerations for the use of micafungin include the potential for hepatotoxicity and gastrointestinal disturbance, the incidence of hepatotoxicity does not appear to differ between caspofungin and micafungin. 19 Less well recognised is the potential for electrolyte disturbances, in particular hyponatraemia that has been described in patients with chronic pulmonary aspergillosis early after the initiation of therapy. 20 Anidulafungin is not metabolised by the liver, so does not have the same propensity for hepatotoxicity and interactions; however, hypomagnesaemia, hypokalaemia and headaches are common adverse events. Of the three agents, only micafungin does not require dose loading at the initiation of therapy. 19 A recent small study of patients with chronic pulmonary aspergillosis demonstrated that micafungin could be safely administered via OPAT. arrhythmias, hypotension and bronchospasm. 23 Electrolyte disturbance, nephrotoxicity and anaemia are commonly reported adverse effects. 24 The risk of nephrotoxicity is increased with use of the deoxycholate preparation vs lipid-based formulations, total cumulative dose, administration of additional nephrotoxic agents and baseline renal dysfunction. 25 It has been postulated that administration of saline prior to infusion of amphotericin B may reduce the risk of nephrotoxicity. 26 Prior to commencing therapy, a test dose is recommended to ensure the patient does not experience a severe hypersensitivity reaction. 27 Pre-treatment with hydrocortisone and chlorphenamine appears to reduce the incidence of infusion-related effects. 28 Renal function should be monitored daily on initiation of therapy with amphotericin B, 28 meaning that initiation of therapy may be challenging in the OPAT setting, and a period of hospital admission may be required to initiate therapy.
| PATIENT S ELEC TI ON & MONITORING
Although there are specific indications for these agents, they are often used as second-line therapy when patients cannot receive triazole therapy due to intolerance or resistance. 18, 29 Recent expert opinion on the management of triazole resistant Aspergillus fumigatus recommend therapy with either liposomal amphotericin B or an echinocandin combined with voriconazole. 30 With triazole resistance in Aspergillus fumigatus increasing worldwide, 31 it is likely that an increasing number of patients requiring treatment will have to receive parenteral therapy instead of an oral triazole agent.
| INFEC TI ON S C AUS ED BY C ANDIDA S PP
Invasive candidiasis (IC) is the most common invasive fungal infection in the developed world and has strong associations with medical intervention, in particular central venous catheters, recent (most commonly intra-abdominal) surgery and broad-spectrum antimicrobial use. 32 The incidence of IC is increasing 33, 34 and is particularly common in critical care environments. The epidemiology will differ depending on the patient cohort treated, trends of antifungal use, and geographically. 35 With the increased use of fluconazole, the incidence of inherently fluconazole resistant spp. such as C. glabrata and C. krusei increases. 36, 37 Additionally, echinocandin resistance is now recognised to occur and is as high as 12% of Candida spp. in some series. 38 The emergence of multi-drug resistant Candida spp.
such as Candida auris will add to the challenge of treating IC and may increase the need to consider OPAT in the treatment of these patients. 39 Obtaining a microbiological diagnosis in invasive candidosis can be difficult, with sensitivity of blood cultures being estimated at approximately 50% in patients with invasive candidiasis. 40 Chronic hepatosplenic candidiasis also requires prolonged antifungal therapy until there is resolution on imaging, often for months.
Initial therapy for the first few weeks should be with an echinocandin or liposomal amphotericin B before stepping down to oral fluconazole if the isolate is fluconazole susceptible, or if the risk of fluconazole resistance is deemed to be low. 29 The spectrum of infections caused by Candida spp. is diverse but many patients could be considered for OPAT early in the course of their illness if clinically stable, investigations for metastatic disease have been carried out, and are otherwise fit for discharge.
Echinocandins remain the initial therapy of choice for invasive infections, with current recommendations stating therapy should be continued for a minimum of 10 days before switch to oral azole is considered where appropriate. 43 In patients with complicated disease or resistant isolates, where oral therapy may not be an option, therapy on OPAT should be pursued if stable.
| INFEC TI ON S C AUS ED BY A SPERG ILLUS S PP
Infections caused by Aspergillus spp., including invasive aspergillosis (IA), chronic pulmonary aspergillosis (CPA) and osteoarticular infections may be amenable to therapy with OPAT. Due to underlying comorbidities, patients with IA are likely to require stabilisation with inpatient therapy prior to consideration of discharge, whereas patients with CPA are more likely to be ambulant. 45 Whilst triazoles remain as first line therapy for infections due to Aspergillus spp.,
liposomal Amphotericin B and echinocandins may be used for a variety of reasons, including azole intolerance, resistance or salvage therapy. 18, 46 Resistant Aspergillus spp. can be acquired from the environment, or arise due to previous triazole exposure, and patterns of resistance may differ. 47 The risks for the development of resistance whilst on triazole therapy include the burden of Aspergillus infection, subtherapeutic serum triazole levels and patient nonadherence. 45 Triazole resistance has been increasingly identified in Aspergillus fumigatus, particularly in Europe. The prevalence of triazole resistance in A. fumigatus is approx. 3.2% with some European countries reporting resistance rates as high as 26%. 48 Mutations in the cyp51A gene which encodes fungal lanosterol 14a-demethylase, the target of azoles, have led to the development of pan-azole resistant A. fumigatus isolates. 47 It should be noted that whilst the echinocandins may be used as salvage therapy, they are not recommended as monotherapy in the primary treatment of IA. 18, 46 The duration of therapy for Aspergillus infection is dependent on the indication. Whilst patients with IA generally receive up to 12 weeks of therapy, patients with CPA often receive prolonged triazole therapy lasting 6 months or more. 18, 46 When parenteral therapy is considered in CPA patients, short courses of up to 6 weeks or intermittent therapy may be attempted. 46 In patients with CPA, short course (2-4 weeks) micafungin is equivalent to voriconazole, with a favourable side effect profile. 49 Caspofungin and micafungin appear equivalent in improving the health status of patients with CPA. 50 In a small series of patients with sarcoidosis and progressive CPA, cyclical caspofungin resulted in stabilisation of radiological appearance and lung function. 51 A retrospective study of intravenous liposomal amphotericin B in CPA demonstrated high response rates (76.6% for repeated courses <6 weeks duration), but increased risk of acute kidney injury with repeated courses of therapy. 52 In general, the use of parenteral therapy in CPA should be reserved for patients with progressive disease, triazole resistance and/or those who fail or are intolerant of triazoles. 
| INFEC TI ON S C AUS ED BY CRYPTOCOCCUS S PP
Cryptococcus neoformans is the leading cause of fungal meningitis in severely immunocompromised patients, particularly in association with HIV infection, with the largest burden of disease found in Subsaharan Africa and South East Asia. 56 Induction therapy with liposomal amphotericin B with oral flucytosine recommended for a minimum of 2 weeks before switching to oral fluconazole, if flucytosine is not included induction therapy is likely to be longer. 54 Cryptococcus gattii, once thought to be a subtype of C. neoformans, has been associated with CNS and pulmonary manifestations in both immunocompetent and immunocompromised patients; some strains of C. gattii, particularly of the VGII molecular type, are associated with reduced susceptibility to fluconazole and may require parenteral therapy. 57 Treatment for Cryptococcosis on OPAT could be considered when the patient is clinically stable and no longer has a requirement for regular lumbar puncture to reduce intracranial pressure.
Flucytosine requires close monitoring for myelosuppression with full blood count. Whilst maintenance therapy is usually in the form of fluconazole, an alternative approach is weekly liposomal amphotericin B, particularly in the case of azole intolerance. 58 
| MUCORMYCOS IS
Mucorales can cause aggressive rhino-orbital, pulmonary, cutaneous or disseminated infections in patients with severe immunocompromise, neutropenia or diabetes. 59 The most commonly associated organisms include Rhizopus, Mucor, Lichtheimia, Cunninghamella and Rhizomucor. Amphotericin B remains the recommended first line therapy, with isavuconazole or posaconazole as alternatives. 60, 61 The optimal duration of therapy is not clear.
Patients with rhino-orbital and cutaneous disease require surgical intervention. 60 Those who require ongoing surgical review and debridement should not be considered for OPAT until surgical excision is considered complete. When surgical management is no longer needed, following physiological stabilisation, continuation of therapy with liposomal amphotericin B on OPAT could be considered, provided close follow-up with an infection specialist is available.
| INFEC TI ON S C AUS ED BY FUSARIUM S PP
After Aspergillus spp., Fusarium spp. is the most common pathogenic mould seen in the setting of solid organ transplant recipients or patients with haematological malignancy, usually presenting as persistent fever with evidence of cutaneous or sinopulmonary disease. Voriconazole or amphotericin B should be used in conjunction with surgical debridement, where possible. 62 As with IA and mucormycosis, where localised disease can be surgically excised,
OPAT could be considered when surgical debridement is deemed to be complete, immunocompromise has improved and physiological stability has been achieved. After a period of parenteral therapy, patients with fusariosis may be able to transition to oral triazole to continue prolonged treatment, potentially with a period of secondary prophylaxis, such an approach could be successfully managed in the controlled environment of an OPAT service. A carefully selected cohort of patients could benefit from OPAT and this should be considered by clinicians responsible for their care.
| CON CLUS IONS
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